Table 1.
Characteristics | Values |
---|---|
All COVID-19 cases (n = 83,811) | |
Age | |
Mean – years | 32.76 |
Distribution – % | |
0–9 | 10.50 |
10–19 | 9.81 |
20–29 | 19.71 |
30–39 | 27.79 |
40–49 | 17.11 |
50–59 | 9.69 |
60–69 | 3.83 |
70–79 | 1.12 |
80–89 | 0.39 |
90–99 | 0.06 |
100+ | 0.001 |
Male sex – % | 66.37 |
Nationality – % | |
Eastern Mediterranean Region | 63.67 |
South-East Asia Region | 33.36 |
Western Pacific Region | 1.34 |
African Region | 1.10 |
Region of the Americas | 0.28 |
European Region | 0.24 |
Symptomatic – % | 32.83 |
Outcomes – % (n) | |
Discharged | 97.14 (81,418) |
Admitted to hospital/Isolation facility | 54.5 (45,891) |
Active | 2.46 (2062) |
Admitted to ICU | 0.7 (623) |
Death | 0.39 (331) |
Clinically admitted COVID-19 patients (n = 1792) | |
Mean age – years | 45.93 |
Male sex – % | 59.0 |
Bahraini Nationality – % | 56.6 |
Smoking history – % | |
Never smoked | 96.66 |
Former smoker | 1.32 |
Current smoker | 2.02 |
Symptoms – % | |
Symptomatic | 63.3 |
Cough | 42.0 |
Fever | 22.4 |
Dyspnea | 20.1 |
Myalgia | 15.5 |
Chest-pain | 8.9 |
Diarrhea | 5.8 |
Nausea/Vomiting | 5.2 |
Anosmia | 3.1 |
Ageusia | 3.0 |
Comorbidities – % | |
Hypertension | 29.7 |
Diabetes mellitus | 28.9 |
Cardiovascular disease | 10.04 |
Glucose-6-phosphate dehydrogenase deficiency | 9.8 |
Asthma | 4.5 |
Chronic kidney disease | 4.4 |
Obesity | 3.24 |
Sickle cell disease | 2.1 |
Other lung diseases | 0.5 |
Chronic obstructive pulmonary disease | 0.4 |
Disease severity on admission – % (n) | |
Admitted on room air | 88.11 (1578) |
Admitted and on oxygen support | 11.28 (202) |
Admitted and on NIV/HFNC | 0.45 (8) |
Invasive ventilation | 0.17 (3) |
Outcomes | |
Mean length of stay – days (IQR) | 10.56 (6–13) |
Length of stay (survivors) – days (IQR) | 10.4 (6–13) |
Length of stay (non-survivors) – days (IQR) | 14.4 (5–19) |
Ventilated (non-invasive and invasive) – % | 8.31 |
Intubated – % | 2.62 |
Extubated – % | 36.17 |
Died – % | 3.29 |
NIV, non-invasive ventilation; HFNC, high-flow nasal cannula.